RhumbLine Advisers’s Fate Therapeutics FATE Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q2 | $175K | Buy |
|
|||||
|
2025
Q1 | $119K | Sell |
|
|||||
|
2024
Q4 | $263K | Buy |
|
|||||
|
2024
Q3 | $549K | Sell |
|
|||||
|
2024
Q2 | $525K | Buy |
|
|||||
|
2024
Q1 | $1.06M | Buy |
|
|||||
|
2023
Q4 | $525K | Sell |
|
|||||
|
2023
Q3 | $298K | Buy |
|
|||||
|
2023
Q2 | $660K | Buy |
|
|||||
|
2023
Q1 | $664K | Buy |
|
|||||
|
2022
Q4 | $1.15M | Buy |
|
|||||
|
2022
Q3 | $2.47M | Buy |
|
|||||
|
2022
Q2 | $2.51M | Buy |
|
|||||
|
2022
Q1 | $3.46M | Buy |
|
|||||
|
2021
Q4 | $5.18M | Sell |
|
|||||
|
2021
Q3 | $5.43M | Buy |
|
|||||
|
2021
Q2 | $7.77M | Buy |
|
|||||
|
2021
Q1 | $7.38M | Sell |
|
|||||
|
2020
Q4 | $8.66M | Buy |
|
|||||
|
2020
Q3 | $3.57M | Sell |
|
|||||
|
2020
Q2 | $3.53M | Buy |
|
|||||
|
2020
Q1 | $1.95M | Buy |
|
|||||
|
2019
Q4 | $1.66M | Buy |
|
|||||
|
2019
Q3 | $1.21M | Buy |
|
|||||
|
2019
Q2 | $1.56M | Sell |
|
|||||
|
2019
Q1 | $1.41M | Buy |
|
|||||
|
2018
Q4 | $1.02M | Buy |
|
|||||
|
2018
Q3 | $718K | Sell |
|
|||||
|
2018
Q2 | $534K | Buy |
|
|||||
|
2018
Q1 | $433K | Buy |
|
|||||
|
2017
Q4 | $204K | Sell |
|
|||||
|
2017
Q3 | $164K | Buy |
|
|||||
|
2017
Q2 | $133K | Buy |
|